Analyser av Strategic Partners

Analysbevakning

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Orphazyme: In-Court Reconstruction Commenced - Redeye

Redeye significantly lowers its base case following an increasingly precarious situation in Orphazyme, which will continue to push the share...

Redeye • 14 Mar 2022 10:04

Orphazyme: Negative CHMP Trend Vote - Redeye

We give our initial take on the likely rejection of Orphazyme’s EU filing for arimoclomol in Niemann-Picks disease type C.

Redeye • 24 Feb 2022 11:29

Orphazyme: Further details on path forward in US - Redeye

Redeye comments on today’s updated schedule for Orphazyme’s planned NDA resubmission with arimoclomol in NPC.

Redeye • 14 Feb 2022 07:37

Orphazyme: Focus remains on path to regulatory approval for arimoclomol in Europe and the USA - Redeye

Orphazyme remains committed to pursuing a path to regulatory approval in Europe and the United States, for arimoclomol in NPC despite a Comp...

Redeye • 31 Aug 2021 17:06